CYP17A1 is an important target for the treatment of prostate cancer that proliferates in response to androgens [19,23] Genetic variation of CPY17A1 was found to be associated with increased risk of prostate cancer [24,25,26,27,28]. Here, CYP17A1 is linked to prostate cancer.